**Supplement no. 8: Course of disease case no. 8**

|  |  |  |  |
| --- | --- | --- | --- |
| **Year** | **Date** | **Therapy** | **Staging** |
| **2017** | 03/2017 |  | initial diagnosis of a NEC G3 of the duodenum with multiple liver metastasessynaptophysin+, chromogranin+, CDX2+, CD56-, TTF –, Insulin-, serotonin-, CD3-, CD20 – |
|  | 03/2017-01/2018 | carboplatin/etoposide |  |
| **2018** | 01/2018 |  | PD |
|  | 02-05/2018 | FOLFOX6 |  |
|  | 05-07/2018 | FOLFIRI |  |
|  | 07/2018 |  | PD |
|  | 12/18-02/19 | pembrolizumab  | no mutation in EGRF, KRAS, NRAS, BRAF, PIK3CA, HER2NEU, EML4, ALK, RET, ROS.PD-L1 5% |
| **2019** | 02/2019 |  | death due to multiorgan failure |

neuroendocrine carcinoma (NEC), progressive disease (PD)